NCT00739232

Brief Summary

This is a single ascending dose study of HSD-016 to provide the initial assessment of the safety, tolerability, how the drug is absorbed and eliminated, and its effect on the body.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Sep 2008

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 20, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 21, 2008

Completed
11 days until next milestone

Study Start

First participant enrolled

September 1, 2008

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2009

Completed
Last Updated

August 3, 2009

Status Verified

July 1, 2009

Enrollment Period

5 months

First QC Date

August 20, 2008

Last Update Submit

July 31, 2009

Conditions

Healthy Subjects

Keywords

Safety and tolerability of HSD-016

Outcome Measures

Primary Outcomes (1)

  • Safety and Tolerability

    3 months

Secondary Outcomes (1)

  • Profiles of Drug Concentrations

    3 months

Study Arms (2)

Active

ACTIVE COMPARATOR

Active

Drug: HSD-016

Placebo

PLACEBO COMPARATOR

Placebo

Other: placebo

Interventions

HSD-016DRUG
Active
placeboOTHER
Placebo

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Men or women of nonchildbearing potential aged 18 to 50 years inclusive at screening.
  • Healthy as determined by the investigator on the basis of screening evaluations.
  • Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history.

You may not qualify if:

  • No presence or history of any disorder that may prevent the successful completion of the study.
  • No history of drug abuse within 1 year.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Overland Park, Kansas, 66211, United States

Location

MeSH Terms

Interventions

(R)-1,1,1-trifluoro-2-(3-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)propan-2-ol

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

August 20, 2008

First Posted

August 21, 2008

Study Start

September 1, 2008

Primary Completion

February 1, 2009

Study Completion

February 1, 2009

Last Updated

August 3, 2009

Record last verified: 2009-07

Locations

US(1)